To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
Incyte Corporation
Incyte Corporation
Incyte Corporation
Celgene
CTI BioPharma
CTI BioPharma
OHSU Knight Cancer Institute
Fred Hutchinson Cancer Center